📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-17 12:07
122 analysed today
FollowTelegram
122
Today
149,523
All-time analysed
42,890
Positive
6,652
Negative
91,308
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
16 announcements match the current filters (relevance ≥ 5).
Ipca Labs Q1 FY27: Revenue Up 21% to ₹2,788 Cr; FY27 Growth Guidance Raised to 14-16%
Ipca Laboratories delivered a strong performance in Q1 FY27, with consolidated revenue increasing 21% YoY to ₹2,788 cr from ₹2,309 cr. Consolidated EBITDA jumped ~50% YoY to ₹638 cr, with EBITDA margin expanding 449 bps to 22.88% from 18.39%. Domestic formulations grew 13% to ₹1,082 cr, led by a 17.2% growth in the chronic segment, while overall exports expanded 34% to ₹603 cr. On the back of broad-based momentum across domestic, generic, and API businesses, management raised its full-year FY27 revenue growth guidance to 14%-16% (up from 12%-13% previously).
Confidence: HIGH
What changedManagement raised FY27 consolidated revenue growth guidance from 12-13% to 14-16% following strong Q1 performance across formulations, APIs, and exports.
Why it mattersOperating leverage and synergy realization from the Unichem acquisition are beginning to reflect in ~450 bps EBITDA margin expansion and robust chronic-segment outperformance.
Q1 FY27 Consolidated Revenue: ₹2,788 crConsolidated Revenue Growth: 21% YoYConsolidated EBITDA Margin: 22.88%Domestic Formulations Revenue: ₹1,082 crRevised FY27 Revenue Growth Guidance: 14% to 16%
📅 Short termPositive sentiment driven by the guidance upgrade and solid EBITDA delivery despite logistical bottlenecks and raw material cost pressures.
📈 Long termStructural expansion continues as Ipca levers Unichem's US generic platform, completes API source transfers to improve cost efficiency, and expands presence in ROW markets like Australia, New Zealand, and Canada.
⚠ Risk flags
- Logistics headwinds including container shortages and rising shipping freight costs
- Fluctuations in active raw material costs that could impact gross margins
- Regulatory approval timelines for API source transfers to Unichem's portfolio
Key Highlights
Q1 FY27 consolidated revenue grew 21% YoY to ₹2,788 cr compared to ₹2,309 cr in Q1 FY26
Consolidated EBITDA surged 50% YoY to ₹638 cr, with EBITDA margin expanding by 449 bps to 22.88%
Full-year FY27 revenue growth guidance upgraded to 14%-16% from the earlier range of 12%-13%
Domestic formulation sales grew 13% YoY to ₹1,082 cr, outperforming the Indian Pharma Market with chronic therapy growing 17.2%
API business delivered 30% YoY growth to ₹424 cr, while export formulation sales rose 34% to ₹603 cr
👀 What to Watch
Track the integration milestones and margin trajectory of Unichem, the timeline for US FDA approvals on API source changes, and whether elevated freight/material costs pressure margins in upcoming quarters.
72% YoY Consolidated PAT Growth in Q1 FY27; EBITDA Margins Expand to 22.88%
IPCA Laboratories reported a strong start to FY27 with consolidated revenue growing 21% YoY to 2,788.10 cr. Net profit for the quarter surged 72% YoY to 401.89 cr, significantly outpacing revenue growth due to operational efficiencies. Consolidated EBITDA margins saw a sharp expansion to 22.88% from 18.39% in the year-ago period. Growth was supported by a 13% rise in domestic formulations and a robust 34% increase in export income.
Confidence: HIGH
What changedIPCA has delivered a significant step-up in profitability and margin profile compared to the previous year, alongside steady double-digit growth in its core domestic and export markets.
Why it mattersThe sharp margin expansion indicates improved operational leverage and potentially a better product mix, which is critical for a company trading at a P/E of 40.2. Strong export growth suggests successful international market execution.
Consolidated Revenue (Q1): 2,788.10 crConsolidated PAT Growth (YoY): 72%Consolidated EBITDA Margin: 22.88%Export Income: 935.39 crDomestic Formulations Growth: 13%
📅 Short termThe stock is likely to react positively to the significant profit beat and margin expansion, which exceeds recent quarterly performance trends.
📈 Long termStructural growth remains tied to the successful integration of Unichem and Krebs, and the company's ability to maintain higher margins while expanding its US and ROW portfolio.
⚠ Risk flags
- Pending regulatory approvals for Krebs amalgamation
- Price erosion risks in US generic markets
- Integration risks of recent acquisitions
Key Highlights
Consolidated Net Profit increased 72% YoY to 401.89 cr in Q1 FY27
Consolidated EBITDA margins expanded by 449 basis points to 22.88% from 18.39% YoY
Export income grew 34% to 935.39 cr, driven by both formulations and APIs
Domestic formulations revenue reached 1,082.12 cr, a 13% growth over Q1 FY26
Standalone revenue of 2,119.24 cr represents approximately 22% of the TTM revenue of 9,645 cr
👀 What to Watch
Investors should monitor the sustainability of the 22%+ EBITDA margins and the progress of the Krebs Biochemicals & Industries Ltd. amalgamation, which has an appointed date of April 1, 2026.
Rs 6 Dividend: IPCA Laboratories Sets August 7, 2026, as Record Date
IPCA Laboratories has fixed August 7, 2026, as the record date for a final dividend of Rs 6 per equity share (600% of face value). The dividend is subject to shareholder approval at the Annual General Meeting (AGM) scheduled for August 13, 2026. If sanctioned, the payment will be processed on or before September 10, 2026. At the current market price of Rs 1826.2, this represents a modest dividend yield of approximately 0.33%.
Confidence: HIGH
What changedThe company has officially scheduled the record date and payment timeline for its annual dividend distribution.
Why it mattersThis is a routine capital allocation event providing a cash return to shareholders, though the yield is relatively low at 0.33% compared to the current stock price.
Dividend per share: Rs 6Dividend Yield: 0.33%Record Date: 07-Aug-2026AGM Date: 13-Aug-2026Payment Deadline: 10-Sep-2026
📅 Short termThe stock price may see a minor adjustment on the ex-dividend date reflecting the Rs 6 payout per share.
📈 Long termLimited structural impact; reflects the company's consistent but conservative dividend policy relative to its TTM PAT of Rs 1187 Cr.
Key Highlights
Dividend declared at Rs 6 per equity share of face value Rs 1 each (600%)
Record date for determining shareholder entitlement is Friday, August 7, 2026
Annual General Meeting (AGM) to be held on August 13, 2026, for final approval
Dividend payment to be completed on or before September 10, 2026
Dividend payout represents approximately 13.3% of the TTM EPS of Rs 44.98
👀 What to Watch
Investors interested in the dividend must hold the shares before the ex-dividend date (typically one working day prior to the record date). Monitor the AGM results on August 13 for formal confirmation of the payout.
IPCA Labs Announces Rs 6 Dividend; 76th AGM Scheduled for August 13, 2026
IPCA Laboratories has scheduled its 76th Annual General Meeting (AGM) for August 13, 2026, to be held via video conferencing. The Board has recommended a final dividend of Rs 6 per share (600%) for the financial year ended March 31, 2026. The company has fixed August 7, 2026, as the record date for dividend eligibility, with payment expected by September 10, 2026. This dividend represents a payout of approximately 13.3% of the TTM EPS of Rs 44.98.
Confidence: HIGH
What changedThe company has formalized the schedule for its 76th AGM and established the record date for the FY26 final dividend distribution.
Why it mattersThis is a routine but necessary administrative event that confirms the timeline for shareholder returns and provides a forum for management to discuss the company's strategic progress.
Dividend per share: Rs 6Dividend % of Face Value: 600%Dividend Payout vs TTM EPS: ~13.3%Record Date: August 7, 2026AGM Date: August 13, 2026
📅 Short termThe stock is likely to trade ex-dividend around the record date of August 7, 2026, which may lead to a minor price adjustment.
📈 Long termLimited structural significance as this is a routine annual administrative and dividend announcement.
Key Highlights
Final dividend of Rs 6 per share (600%) recommended for FY 2025-26
76th Annual General Meeting scheduled for August 13, 2026, at 3:30 p.m.
Record date for dividend entitlement fixed as August 7, 2026
Remote e-voting period set from August 10 (9:00 a.m.) to August 12, 2026 (5:00 p.m.)
Dividend payment to be completed on or before September 10, 2026
👀 What to Watch
Investors should ensure their demat account details are updated before the August 7 record date to receive the Rs 6 dividend. Monitor the AGM proceedings for management commentary on the Unichem integration and US market expansion.
IPCA Laboratories to Merge Krebs Biochemicals; Sets Swap Ratio at 7:200
IPCA Laboratories has approved the merger of Krebs Biochemicals & Industries Ltd. into itself to secure its supply chain for critical fermentation-based APIs. The swap ratio is fixed at 7 equity shares of IPCA for every 200 shares of Krebs. While Krebs is significantly smaller with a turnover of ₹26 crore compared to IPCA's ₹7,431 crore, the merger provides IPCA with specialized manufacturing facilities it currently lacks. This strategic move aims to stabilize the supply of ingredients for IPCA's largest selling formulations and optimize costs through operational synergies.
Key Highlights
Swap ratio of 7 fully paid-up equity shares of IPCA (Re 1 each) for every 200 shares of Krebs (Rs 10 each).
IPCA's FY26 standalone income was ₹7,431 Crores, while Krebs reported ₹26 Crores, primarily from conversion charges.
The merger secures the supply of a key fermentation-based API used in IPCA's largest selling formulation.
IPCA's promoter shareholding will see a marginal dilution from 44.72% to 44.66% post-merger.
The scheme is set with an appointed date of April 1, 2026, pending regulatory and shareholder approvals.
👀 What to Watch
Investors should view this as a strategic backward integration that secures critical raw materials and R&D capabilities. While the immediate financial impact on IPCA's bottom line is negligible due to the target's small size, it strengthens the long-term supply chain resilience.
Ipca Laboratories to Merge Krebs Biochemicals; Swap Ratio Set at 7:200
Ipca Laboratories has approved the merger of Krebs Biochemicals & Industries Ltd. into itself to secure its supply chain for fermentation-based APIs. The share swap ratio is fixed at 7 equity shares of Ipca for every 200 shares of Krebs. While Krebs is relatively small with an annual income of ₹26 crore compared to Ipca's ₹7,431 crore, the merger provides Ipca with critical manufacturing capabilities and drug intermediates it currently lacks. This strategic vertical integration is expected to optimize costs and streamline regulatory compliances.
Key Highlights
Share swap ratio of 7 equity shares of Ipca (Re. 1 face value) for every 200 shares of Krebs (Rs. 10 face value).
Ipca's standalone total income for FY26 stood at ₹7,431 crore, while Krebs reported ₹26 crore.
The merger aims to secure uninterrupted supply of fermentation-based APIs used in Ipca's largest selling formulations.
Post-merger, Ipca's promoter shareholding will marginally decrease from 44.72% to 44.66%.
The appointed date for the scheme of amalgamation is April 1, 2026, subject to regulatory approvals.
👀 What to Watch
Investors should view this as a strategic move to strengthen Ipca's supply chain and R&D capabilities in fermentation-based APIs. Monitor the progress of regulatory approvals and the integration of Krebs' manufacturing facilities.
Ipca Labs Signs Global Licensing Deal with BRL for Subcutaneous Biologics Delivery Platform
Ipca Laboratories has entered into a definitive global licensing agreement with Bhami’s Research Laboratory (BRL) to access a proprietary high-concentration subcutaneous biologics delivery platform. This collaboration aims to develop and commercialize multiple monoclonal antibody products targeting oncology and inflammatory diseases across major markets including the USA, EU, and India. Under the agreement, BRL will receive milestone fees for technology transfer and royalties on net sales post-commercialization. The initiative leverages Ipca's existing bio-manufacturing facility in Pithampur and its R&D center in Mumbai to strengthen its biosimilar portfolio.
Key Highlights
Global licensing agreement granting Ipca access to BRL's proprietary subcutaneous delivery technology.
Focuses on monoclonal antibody products for oncology and inflammatory diseases for worldwide markets.
Ipca to manage clinical trials, commercial manufacturing, and global launch across 120+ countries.
Financial structure includes defined milestone fees for technology transfer and royalties on future net sales.
Strategic expansion of Ipca's biosimilar capabilities using its Pithampur bio-manufacturing and Mumbai R&D facilities.
👀 What to Watch
Investors should monitor the progress of technology transfer and subsequent clinical trial milestones, as this partnership marks a significant move into high-margin biologics. This is a long-term value driver that could diversify Ipca's revenue streams beyond traditional APIs and generics.
IPCA Labs Q4 FY26: Standalone EBITDA Margins Surge to 25.27% Amid 12% Domestic Growth
IPCA Laboratories reported a 12% growth in its domestic formulation business for Q4 FY26, reaching INR 853 crores. Standalone EBITDA margins improved significantly by 4.08% YoY to 25.27%, driven by a better product mix and cost management. For the full year FY26, consolidated revenue grew 8% to INR 9,646 crores with an EBITDA margin of 20.72%. Management has guided for 12-13% consolidated revenue growth and improved margins of 22-22.3% for FY27.
Key Highlights
Domestic formulation business grew 12% in Q4 FY26 to INR 853 crores
Standalone EBITDA margins expanded to 25.27% in Q4 FY26 from 21.19% YoY
Consolidated FY26 revenue reached INR 9,646 crores, an 8% increase over FY25
U.S. consolidated business (including Unichem) grew 14% in FY26 to INR 1,567 crores
Management projects FY27 consolidated revenue growth of 12-13% and EBITDA margins of 22-22.3%
👀 What to Watch
Investors should remain positive on the stock due to strong domestic performance and margin expansion, while monitoring the recovery of Unichem's margins. The company's ability to pass on rising API input costs to buyers is a key operational strength to watch.
IPCA Labs Recommends ₹6 Final Dividend; FY26 Net Profit Surges 74% to ₹1,132 Crore
IPCA Laboratories has recommended a final dividend of ₹6 per share (600%) for FY26, with the record date set for August 7, 2026. The company reported a strong financial performance for the full year, with standalone revenue growing 9.8% to ₹7,336.75 crore. Net profit saw a significant jump of 74%, reaching ₹1,132.52 crore compared to ₹650.76 crore in the previous fiscal, aided by lower exceptional items. Additionally, the board approved the re-appointment of Mr. Prashant Godha as Executive Director for a five-year term.
Key Highlights
Recommended final dividend of ₹6 per equity share (600% of FV ₹1) for FY26
Standalone Net Profit grew 74% YoY to ₹1,132.52 crore from ₹650.76 crore
Annual Revenue from operations increased by 9.8% to ₹7,336.75 crore
EPS (after exceptional items) rose significantly to ₹44.64 from ₹25.65 in FY25
Record date for dividend entitlement is fixed as Friday, August 7, 2026
👀 What to Watch
Investors should benefit from the healthy dividend payout and the strong recovery in net margins. The significant growth in bottom-line performance makes it a positive outlook for long-term holders.
Ipca Labs FY26 PAT Surges 74% to ₹1,133 Cr; Recommends ₹6 Dividend
Ipca Laboratories reported a strong financial performance for FY26, with standalone revenue growing 9.8% YoY to ₹7,336.75 crore. Net profit saw a significant jump of 74% to ₹1,132.52 crore, largely aided by a reduction in exceptional items compared to the previous fiscal year. The Board has recommended a final dividend of ₹6 per share (600%) and ensured leadership continuity by re-appointing Mr. Prashant Godha as Executive Director for a further five-year term starting August 2026.
Key Highlights
Standalone Revenue from operations increased 9.8% YoY to ₹7,336.75 crore in FY26.
Net Profit (PAT) surged 74% to ₹1,132.52 crore from ₹650.76 crore in FY25.
Recommended a dividend of ₹6 per equity share (600%) with a record date of August 7, 2026.
Earnings Per Share (EPS) improved significantly to ₹44.64 from ₹25.65 in the previous year.
Mr. Prashant Godha re-appointed as Executive Director for a 5-year term effective August 16, 2026.
👀 What to Watch
The strong recovery in profitability and healthy dividend payout are positive signals for long-term investors. Shareholders should approve the dividend and management re-appointment at the upcoming AGM while monitoring the impact of new labor code provisions.
IPCA Labs FY26 Standalone Net Profit Surges 74% to ₹1,133 Cr; Declares ₹6 Dividend
IPCA Laboratories reported a robust performance for the financial year ended March 31, 2026, with standalone revenue growing 9.9% to ₹7,336.75 crore. Net profit for the full year witnessed a significant jump of 74%, reaching ₹1,132.52 crore, supported by operational efficiencies and a 31% reduction in finance costs. The Board has recommended a dividend of ₹6 per share (600%) and approved the re-appointment of Prashant Godha as Executive Director for five years. Despite an exceptional charge of ₹30.42 crore related to new Labour Codes, the overall financial health remains strong with a net worth of ₹7,979.35 crore.
Key Highlights
Standalone Revenue for FY26 grew 9.9% YoY to ₹7,336.75 crore from ₹6,677.92 crore.
Full-year Net Profit increased by 74% to ₹1,132.52 crore compared to ₹650.76 crore in FY25.
Recommended a dividend of ₹6 per equity share (600%) with a record date of August 7, 2026.
Finance costs significantly reduced to ₹43.51 crore in FY26 from ₹63.04 crore in the previous year.
Exceptional item of ₹30.42 crore recognized in Q4 FY26 due to the impact of new Government Labour Codes.
👀 What to Watch
Investors should take note of the strong bottom-line growth and the company's ability to reduce interest burdens. The healthy dividend payout and leadership continuity make it a positive hold for long-term portfolios in the pharmaceutical sector.
IPCA Labs Q3 FY26: Cons. EBITDA Margin Jumps to 22.5%; Domestic Business Grows 12%
IPCA Laboratories reported a strong Q3 FY26 with consolidated EBITDA margins expanding by 228 basis points to 22.5%. The domestic formulation business grew 12%, significantly outpacing the Indian Pharmaceutical Market growth of 8.9%. While the API business remained flat at 317 crores, export formulations saw a robust 17% growth. Management is focusing on biosimilars and the integration of Unichem, which saw 17% growth in its U.S. business during the quarter.
Key Highlights
Consolidated EBITDA margin improved to 22.5% from 19.87% in the same quarter last year.
Domestic formulation business grew 12%, with the core pain segment (50% of domestic sales) growing at 13%.
Export formulations delivered 17% growth, led by a 69% surge in West African markets.
Unichem's U.S. business grew 17% in Q3, though its overall EBITDA margin currently stands at approximately 8%.
The company holds a strong cash position of over 250 crores with minimal major CAPEX planned beyond a 50 crore solar project.
👀 What to Watch
Investors should view the margin expansion and domestic outperformance as strong indicators of operational efficiency. Monitor the profitability turnaround of Unichem and progress in the biosimilar pipeline as key long-term growth catalysts.
IPCA Labs Q3 Consolidated Net Profit Rises 31.5% YoY to ₹326.27 Crore
IPCA Laboratories reported a robust performance for Q3 FY26, with consolidated revenue from operations growing 6.5% YoY to ₹2,392.50 crore. The consolidated net profit attributable to owners surged by 31.5% to ₹326.27 crore, up from ₹248.14 crore in the same quarter last year. The company's nine-month consolidated revenue reached ₹7,257.85 crore, reflecting steady growth. Additionally, the company expanded its international footprint by acquiring 100% of Unichem Laboratories Ireland and incorporating a new subsidiary in Germany.
Key Highlights
Consolidated Revenue from operations increased to ₹2,392.50 Cr from ₹2,245.37 Cr YoY.
Net Profit attributable to owners grew significantly by 31.5% YoY to ₹326.27 Cr.
Nine-month consolidated revenue reached ₹7,257.85 Cr compared to ₹6,692.90 Cr in the previous year.
Completed 100% acquisition of Unichem Laboratories Limited, Ireland, and established a German subsidiary.
Standalone Profit Before Tax (PBT) for the quarter stood at ₹417.22 Cr, up from ₹355.52 Cr YoY.
👀 What to Watch
The strong double-digit profit growth and strategic international expansions indicate healthy business momentum. Investors should maintain a positive outlook while monitoring the integration and performance of the newly acquired international subsidiaries.
IPCA Labs Starts Commercial Production at New Rs 182 Cr Wardha API Facility
IPCA Laboratories has officially commenced commercial production at its new greenfield manufacturing facility located in Wardha, Maharashtra. The facility is dedicated to the production of Drug Intermediates and Active Pharmaceutical Ingredients (APIs), representing a strategic move to enhance its manufacturing footprint. The project was completed with a total capital outlay of approximately Rs. 182 crores. This expansion is expected to strengthen the company's vertical integration and support long-term growth in the API segment.
Key Highlights
Commencement of commercial production at the new greenfield facility in Village Hingani, Wardha.
Total capital expenditure for the new unit is approximately Rs. 182 crores.
The facility focuses on manufacturing Drug Intermediates and Active Pharmaceutical Ingredients (APIs).
The expansion aligns with IPCA's strategy to bolster its supply chain and API market presence.
👀 What to Watch
Investors should view this expansion positively as it enhances IPCA's API capabilities and potential for margin improvement through backward integration. Monitor the production ramp-up and its contribution to the API segment's revenue in the coming quarters.
IPCA Labs Tarapur API Facility Receives VAI Classification from US FDA
IPCA Laboratories has received the Establishment Inspection Report (EIR) for its Tarapur API manufacturing facility following a US FDA inspection in December 2025. The facility has been classified as 'Voluntary Action Indicated' (VAI), indicating a minimally acceptable state of compliance with current good manufacturing practices (CGMP). This classification is a positive outcome as it typically allows for new product approvals and continued exports to the US market. The inspection was conducted between December 1 and December 5, 2025, and the EIR was received on February 7, 2026.
Key Highlights
US FDA inspection of Tarapur API facility conducted from Dec 1 to Dec 5, 2025
Facility received Establishment Inspection Report (EIR) on Feb 7, 2026
Classification assigned as Voluntary Action Indicated (VAI)
Facility deemed in a minimally acceptable state of compliance with CGMP
👀 What to Watch
This is a positive regulatory milestone that reduces risk for the company's US-bound API business. Investors may view this as a clearance for potential new product launches from this specific manufacturing site.
IPCALAB: US FDA inspects Tarapur API facility, issues Form 483 with 3 observations
The US FDA conducted an inspection of IPCA Laboratories' Active Pharmaceutical Ingredients (APIs) manufacturing facility in Tarapur (Palghar-Maharashtra) from December 1st to December 5th, 2025. Following the inspection, the US FDA issued a Form 483, which included 3 observations. IPCA Laboratories plans to submit a comprehensive response to the US FDA within the stipulated timeframe. The company is committed to resolving the issues and maintaining high standards of quality and compliance.
Key Highlights
US FDA inspected IPCA's API facility in Tarapur from December 1st to 5th, 2025
US FDA issued a Form 483 with 3 observations
IPCA will respond to US FDA within the stipulated time
👀 What to Watch
Investors should monitor IPCA's response to the US FDA's observations and any subsequent updates regarding the facility's compliance status. Any negative resolution could impact future revenue.
